drugset / Trial / NCT00402350

Staccato Fentanyl Single and Multidose PK

NCT00402350

Phase 1 Completed 51 enrolled Alexza Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Phase I clinical trial in approximately 50 healthy volunteers will be conducted at a single clinical center in two stages. Stage 1 is an open-label, cross-over comparison of a single dose of Staccato Fentanyl and an equivalent dose of intravenous (IV) fentanyl. Stage 2 is a randomized, doubleblind, placebo-controlled dose escalation of Staccato Fentanyl, evaluating multiple doses of fentanyl. The three primary aims of the Phase I clinical trial are to evaluate the pharmacokinetics (PK) and absolute bioavailability for Fentanyl, compare the Staccato Fentanyl PK profile to the IV fentanyl PK profile, and examine the tolerability and safety of Staccato Fentanyl in a non-opioid-tolerant, healthy volunteer population.

Timeline

Start
2006-04
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 25 ug Inhaled

Indications

No indication recorded.